Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Johnson & Johnson today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment ...

(NASDAQ:ARGX – Free Report) had its price target lifted by Piper Sandler from $620.00 to $725.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has ...

Soleo Health has opened a new ambulatory infusion suite in the metro Denver area to complement its existing home infusion service offerings.

PORTLAND, OR, UNITED STATES, January 6, 2025 /EINPresswire / -- The global immunoglobulin market is experiencing significant growth, driven by the increasing prevalence of immune-related diseases and ...

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report)’s share price gapped down prior to trading on Friday . The stock had previously closed at $25.19, but opened at $24.52. Immunovant shares last traded ...

Korean biotech firms anticipate significant developments in FDA approvals and clinical trials Innovations in medical research ...

Immune globulin (human) is under clinical development by Octapharma and currently in Phase III for Unspecified Neurologic Disorders.

Temelimab is under clinical development by GeNeuro and currently in Phase II for Unspecified Central Nervous System Disorders.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and ...

Dutch immunology specialist argenx announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) approved Vyvdura ...

Vyvdura receives Japanese regulatory approval for adults with chronic inflammatory demyelinating polyneuropathy: Rotterdam, the Netherlands Monday, December 30, 2024, 1 ...